赖脯胰岛素在老年糖尿病患者胰岛素强化治疗的临床研究  

Clinical study on efficacy and security of lispro in the intensive insulin therapy of elderly diabetic patients

作　　者：左莹[1] 雷震[1] 

机构地区：[1]川北医学院附属医院内科,四川南充637000

出　　处：《实用药物与临床》2012年第7期403-405,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的评价赖脯胰岛素优泌乐在老年糖尿病患者胰岛素强化治疗的疗效及安全性。方法 66例血糖控制不佳的老年糖尿病患者(≥65岁)行胰岛素强化治疗,随机分为优泌乐(胰岛素泵)组、优泌乐+优泌林N组、优泌林R+优泌林N组进行强化治疗,比较血糖达标时间、血糖、胰岛素用量、治疗过程中低血糖的发生率。结果两组使用优泌乐治疗的患者与优泌林R+优泌林N组患者相比,其三餐后2 h血糖控制更好(P<0.05),血糖达标时间更短(P<0.05),胰岛素日用量更少(P<0.05),而优泌乐组与优泌乐+优泌林N组相比差异无统计学意义(P>0.05)。三组间低血糖发生率差异无统计学意义(P>0.05)。结论老年糖尿病患者使用优泌乐强化治疗,可有效控制血糖,不增加低血糖的发生率。Objective To study the efficacy and adverse reaction of lispro in the intensive insulin therapy of elderly diabetic patients. Methods 66 elderly diabetic patients （ ≥ 65 years） were randomly divided into lispro group （ insulin pump,22 cases）, lispro ＋ humulin N group （ 22 cases） and humulin R ＋ humulin N group （ 22 cases） to receive intensive insulin therapy for 2 weeks. The time of reaching standard glucose control, glucose level, the total doses of in- sulin and the rate of hypoglycemia were compared among 3 groups. Results After the treatment,2 groups used lispro had better postprandial glucose （ P 〈 0.05 ） , less time of reaching standard glucose control （ P 〈 0. 05 ） and less doses of insuIin （P 〈 0. 05）. There was no significant difference between lispro group and lispro ＋ humulin N group （P 〉 0. 05 ）. However, the rate of hypoglycemia among 3 groups had no significant difference （ P 〉 0. 05 ）. Conclusion Lispro is an effective and safe drug for intensive insulin therapy of elderly diabetic patients.

关 键 词：优泌乐 老年糖尿病 胰岛素强化治疗 胰岛素泵 

分 类 号：R587.1[医药卫生—内分泌]